The clinical progress is a positive step but the real catalyst will be the initiation of the Phase 3 study and eventual data readout. Monitor for Phase 3 start in H2 2026 and any additional funding announcements. The CFO promotion is routine and does not change the investment thesis.
Price Chart
Executive Summary
Armata Pharmaceuticals announced clinical, regulatory, and manufacturing progress for its lead candidate AP-SA02, including submission of the Phase 3 protocol to the FDA and completion of four engineering runs, keeping the Phase 3 superiority study on track for H2 2026. The company also disclosed a $2.5 million DoD award continuation (total $28.7M) and promoted David House to CFO. The clinical update is a positive catalyst but the company remains pre-revenue with no financial results reported.
Key Facts
- Phase 3 superiority protocol for AP-SA02 submitted to FDA; all End-of-Phase 2 meeting comments addressed.
- Four engineering runs of AP-SA02 completed; clinical trial material production is the next manufacturing step.
- Phase 3 study remains on track to initiate in the second half of 2026.
- DoD award continuation of $2.5 million brings total funding under the award to $28.7 million.
- David House promoted to CFO with base salary of $371,315, target bonus of 50%, and annual equity award intent of ~$300,000.
Financial Impact
No revenue or earnings reported. The DoD award provides $2.5M in additional non-dilutive funding, bringing total DoD support to $28.7M. The company is pre-revenue and will require additional capital to fund the Phase 3 study.
Risk Factors
- Clinical trial risk: Phase 3 may fail to meet endpoints.
- Funding risk: Company needs additional capital to execute Phase 3 study beyond existing DoD award.
- Regulatory risk: FDA may require additional data before accepting BLA.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 11 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (ARMP) — Batch item 1 | 0001104659-26-084861 |
| Document: tm2620782d2_ex99-1.htm | 0001104659-26-084860 |
| Document: 0001104659-26-084861-index-headers.html | 0001104659-26-084861 |
| Document: 0001104659-26-084861-index.html | 0001104659-26-084861 |
| Document: 0001104659-26-084861.txt | 0001104659-26-084861 |
| 8-K Filing (ARMP) — Batch item 6 | 0001104659-26-084860 |
| Document: tm2620782d1_8k.htm | 0001104659-26-084861 |
| Document: tm2620782d1_ex10-2.htm | 0001104659-26-084861 |
| Document: 0001104659-26-084860-index-headers.html | 0001104659-26-084861 |
| Document: 0001104659-26-084860-index.html | 0001104659-26-084861 |
| Document: 0001104659-26-084860.txt | 0001104659-26-084861 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $5.55 $4.26 | ▼ −23.24% | ▼ −23.35% | $3.52 (−36.58%) |
Jul 20, 2026 10w ago | 8-K | $5.06 $4.66 | ▼ −7.91% | ▼ −7.48% | $3.52 (−30.43%) |
May 13, 2026 20w ago | 8-K | $8.20 $8.23 | ▼ −0.37% | ▼ −1.08% | $3.52 (+57.07%) |
Apr 27, 2026 22w ago | 8-K | $11.00 $9.85 | ▼ −10.45% | ▼ −10.85% | $3.52 (−68.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access